Robert Kramer was the CEO of Emergent BioSolutions, a government contractor.

(Bloomberg) -- The stock market’s recent wipeout has pushed a quarter of biotechnology stocks to trade below their cash holdings. That’s left bargain-hunters with a choice: Buy the dip or sit this one ...

Zhengye receives a Nasdaq notice for failing to file its 2024 annual report on time. The company has 60 days to submit a compliance plan to avoid potential delisting. Get special access to three ...

I favor biotech stocks trading below cash value after setbacks; Arvinas (ARVN) fits this description, dropping 25% on Thursday after ending two Phase 3 trials. ARVN's net cash per share is over $12, ...

Genenta plans a major shift into defense businesses, backing weapons maker ATC, rebranding as Saentra Forge and reshaping its ...

TRINITY BIOTECH ($TRIB) is expected to release its quarterly earnings data on Thursday, May 22nd before market open, per Finnhub. Analysts are expecting revenue of ...

09:35 EDT Zhengye Biotechnology (ZYBT) Holding Ltd trading halted, volatility trading pause Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor ...

The bear market induced by the Federal Reserve’s monetary tightening officially ended in 2023, but it seems no one remembered to tell the biotech sector. Biotech stocks lagged the broader market in ...

Oncolytics Biotech (NASDAQ:ONCY – Get Free Report)‘s stock had its “hold” rating reissued by research analysts at Jones Trading in a report released on Friday,Benzinga reports. Several other equities ...

SANTA ANA, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of ...